Biofrontera Debiti verso fornitori

Cosa fa Biofrontera? Biofrontera Inc, a US-based pharmaceutical company, operates in the Health Care sector with its headquarters in Woburn, Massachusetts. The company employs 81 full-time staff and completed its initial public offering (IPO) on October 14, 2021. Biofrontera focuses on commercializing pharmaceutical products for dermatological conditions, particularly emphasizing photodynamic therapy (PDT) and topical antibiotics. Its licensed portfolio includes treatments for actinic keratoses, pre-cancerous skin lesions, and impetigo, a bacterial skin infection. The company's principal product, Ameluz, is a prescription drug used in conjunction with the BF-RhodoLED lamp series for photodynamic therapy. In the United States, this treatment is indicated for lesion-directed and field-directed therapy of mild-to-moderate actinic keratoses on the face and scalp. Another key product is Xepi, which is used for treating impetigo caused by Staphylococcus aureus or Streptococcus pyogenes. Xepi is approved for use in adults and children aged two months and older. The company's website, biofrontera-us.com, provides additional information about its products and services. Biofrontera Inc. is listed under the ticker symbol BFRI with ISIN US09077D2099. The company operates within the Pharmaceuticals industry, targeting specific dermatological conditions through its licensed product portfolio. Biofrontera è una delle aziende più popolari su Eulerpool.com.